Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Previously presented) A composition comprising two triglycoside glycoalkaloids in a ratio of between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated.

2. (Previously presented) A composition according to claim 1 wherein the glycoalkaloids are present in a ratio selected from the group of ratios consisting of approximately: 1:6 - 1:0.5; 1:5; 1:4; 1:3; 1:2; 1:1.5 and 1:1.

3. (Previously presented) A composition according to claim 1 wherein the glycoalkaloids are solasodine glycosides.

4. (Original) A composition according to claim 1 wherein the glycoalkaloids are selected from the group consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

5. (Original) A composition comprising about a 1:1 ratio of solamargine and solasonine in isolated form.

6. (Previously presented) A composition comprising two triglycoside glycoalkaloids on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition.

7. (Previously presented) A composition according to claim 6 wherein the glycoalkaloids constitute at least 70%-90% of the glycosides in the composition.

8. (Previously presented) A composition according to claim 6, wherein the glycoalkaloids constitute at least 91-95% of the glycosides in the composition.

9. (Previously presented) A composition according to claim 6, wherein the glycoalkaloids constitute at least 96-100% of the glycosides in the composition.

10. (Previously presented) A composition according to claim 6 wherein the ratio of the two glycoalkaloids is a ratio selected from the group of ratios consisting of: 1:5; 1:4; 1:3; 1:2 and 1:1.

11. (Original) A composition according to claim 6 wherein the glycoalkaloids are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

12. (Original) A composition comprising solamargine and solasonine in a ratio between about 1:6 and 6:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

13. (Original) A composition comprising solamargine and solasonine in a ratio between about 1:4 and 4:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

14. (Original) A composition comprising solamargine and solasonine in a ratio between about 1:3 and 3:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

15. (Original) A composition comprising solamargine and solasonine in a ratio between about 1:2 and 2:1 on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

16. (Original) A composition comprising a 1:1 ratio of solamargine and solasonine on the proviso that the solasonine and solamargine do not constitute 66% of the glycosides in the composition.

17. (Previously presented) A composition consisting essentially of two triglycoside glycoalkaloids.

18-20. (Canceled)

21. (Previously presented) A composition according to claim 17 wherein the ratio of the glycoalkaloids in the composition is selected from the group of ratios consisting of: 1:5; 1:4; 1:3; 1:2 and 1:1.

22. (Original) A composition according to claim 17 wherein the glycoalkaloids are selected from the group of glycoalkaloids consisting of: solamargine, solasonine, solanine, tomatine, solanocapsine and 26-aminofurostane.

23. (Previously presented) A composition consisting essentially of solamargine and solasonine in a ratio between about 1:6 and 6:1.

24. (Original) A composition consisting essentially of about a 1:1 ratio of solamargine and solasonine.

25. (Currently amended) A composition according to claim 1 comprising about 0.001% - 5% triglycoside glycoalkaloids.

26. (Currently amended) A composition according to claim 1 comprising about 10% triglycoside glycoalkaloids.

27. (Previously presented) A pharmaceutical composition comprising a composition of claim 1 and a pharmaceutically acceptable carrier.

28. (Original) A pharmaceutical composition according to claim 27 adapted for topical delivery.

29. (Original) A pharmaceutical composition according to claim 27 adapted for oral delivery.

30. (Original) A pharmaceutical composition according to claim 27 adapted for parenteral delivery.

31. (Previously presented) A method of treating cancer in a subject comprising the step of administering to the subject an effective amount of a composition comprising two triglycoside glycoalkaloids in a ratio of between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or a pharmaceutical composition of claim 27.

32. (Previously presented) A method of treating psoriasis in a subject comprising the step of administering to the subject an effective amount of a composition comprising two triglycoside glycoalkaloids in a ratio of between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or a pharmaceutical composition of claim 27.

33. (Previously presented) A method of treating abnormal cell growth in a patient comprising the step of administering an effective amount of a composition comprising two triglycoside glycoalkaloids in a ratio of between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or a pharmaceutical composition of claim 27.

34. (Previously presented) A method of diagnosing abnormal cell growth in a subject comprising the step of applying a composition comprising two tryglycoside glycoalkaloids in a ratio of between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated, or pharmaceutical composition of claim 27 to a test area on said subject and then monitoring said test area for inflammation.

35. (Original) A method according to claim 34 wherein the diagnostic is for skin cancers such as keratoses, basal cell carcinomas, squamous cell carcinomas and melanomas.

36. (Previously presented) A composition of claim 1 further comprising a detectable label.

37. (Previously presented) A method for detecting a target cell comprising the steps of applying a composition according to claim 36 to a sample or a subject and detecting the label.

38. (Previously presented) A composition according to claim 6 comprising about 0.001% - 5% glycoalkaloids.

39. (Previously presented) A composition according to claim 17 comprising about 0.001% - 5% glycoalkaloids.

40. (Previously presented) A composition according to claim 6 comprising about 10% glycoalkaloids.

41. (Previously presented) A composition according to claim 17 comprising about 10% glycoalkaloids.

42. (Previously presented) A pharmaceutical composition comprising a composition of claim 6 and a pharmaceutically acceptable carrier.

43. (Previously presented) A pharmaceutical composition comprising a composition of claim 17 and a pharmaceutically acceptable carrier.

44. (Previously presented) A method of treating cancer in a subject comprising the step of administering to the subject an effective amount of a composition comprising two triglycoside glycoalkaloids on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition.

45. (Canceled)

46. (Previously presented) A method of treating psoriasis in a subject comprising the step of administering to the subject an effective amount of a composition comprising two triglycoside glycoalkaloids on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition.

47. (Canceled)

48. (Previously presented) A method of treating abnormal cell growth in a patient comprising the step of administering an effective amount of a composition comprising two triglycoside glycoalkaloids on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition.

49. (Canceled)

50. (Previously presented) A method of diagnosing abnormal cell growth in a subject comprising the step of applying a composition comprising two triglycoside glycoalkaloids on the proviso that when the glycoalkaloids are solasonine and solamargine they do not constitute 66% of glycosides in the composition, to a test area on said subject and then monitoring said test area for inflammation.

51. (Canceled)

52. (Previously presented) A composition of claim 6 further comprising a detectable label.

53. (Previously presented) A composition of claim 17 further comprising a detectable label.

54. (Previously presented) A composition consisting essentially of solamargine and solasonine in a ratio between about 1:4 and 4:1.

55. (Previously presented) A composition consisting essentially of solamargine and solasonine in a ratio between about 1:3 and 3:1.

56. (Previously presented) A composition consisting essentially of solamargine and solasonine in a ratio between about or 1:2 to 2:1.

57. (Previously presented) A method according to claim 50 wherein the diagnostic is for skin cancers such as keratoses, basal cell carcinomas, squamous cell carcinomas and melanomas.

58. (Previously presented) A method for detecting a target cell comprising the steps of applying a composition according to claim 52 to a sample or a subject and detecting the label.

59. (Previously presented) A method of treating cancer in a subject comprising the step of administering to the subject an effective amount of a composition consisting essentially of two triglycoside glycoalkaloids.

60. (Previously presented) A method of treating psoriasis in a subject comprising the step of administering to the subject an effective amount of a composition consisting essentially of two triglycoside glycoalkaloids.

61. (Previously presented) A method of treating abnormal cell growth in a subject comprising the step of administering to the subject an effective amount of a composition consisting essentially of two triglycoside glycoalkaloids.

62. (Previously presented) A method of diagnosing abnormal cell growth in a subject comprising the step of administering to the subject an effective amount of a composition consisting essentially of two triglycoside glycoalkaloids.

63. (Previously presented) A method according to claim 62 wherein the diagnostic is for skin cancers such as keratoses, basal cell carcinomas, squamous cell carcinomas and melanomas.

64. (Previously presented) A method for detecting a target cell comprising the steps of applying a composition according to claim 53 to a sample or a subject and detecting the label.